Immatics NV

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

Immatics (IMTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)

Immatics showcases a robust financial position and promising IMA203 TCR-T cell therapy for oncology with impressive safety and efficacy data. Risks include high competition in T-cell therapies, potential dilution from EPS of -$0.34, and an 11.11% short interest implying some bearish sentiment. Investment Recommendation: "Buy" with close monitoring of the 4Q 2023 clinical update; offers high-reward potential but be prepared for short-term volatility.

Analyzing Immatics' Multi-Faceted Investment Case

Protalix Biotherapeutics

Appointment effective as of September  14, 2023; Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel , Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that the Company's Board of Directors has appointed Eliot Richard Forster, Ph.D.

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

Moderna

Immatics NV's shares rose Monday after it announced a collaboration with Moderna Therapeutics Inc (NASDAQ:MRNA) to pioneer novel and transformative therapies for cancer patients with high unmet medical need. Under the agreement, the German drug developer will receive an upfront payment of $120 million.

Immatics inks deal worth $120M to $1.7B with Moderna to boost cancer vaccine development

Immatics NV shares IMTX, -2.87% gained more than 6% premarket on Monday after the company announced a collaboration with Moderna Inc. MRNA, -0.66% to research and develop new cancer therapies. The partnership couples Immatics' T cell-redirecting cancer immunotherapy platform with Moderna's mRNA technology and is expected to span bispecifics, cell therapy and cancer vaccines, the companies said in a release Monday.

Immatics shares rise on Moderna cancer collaboration

Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer $120 million in cash and additional milestone payments.

Moderna, Immatics to work jointly on cancer vaccines

Cambridge, Massachusetts and Tuebingen , Germany , September 11 , 2023 – Moderna, Inc. (NASDAQ: MRNA, “Moderna”) and Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics' TCR platform with Moderna's cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna's mRNA technology for the development of novel cancer vaccines Collaboration to include evaluation of Immatics' investigational IMA203 PRAME TCR-T in combination with Moderna's investigational PRAME mRNA cancer vaccine Immatics to receive $120 million upfront cash payment plus research funding with the potential for additional milestone and royalty payments CAMBRIDGE, MA and TUEBINGEN, GERMANY / ACCESSWIRE / September 11, 2023 / Moderna, Inc. (NASDAQ:MRNA, "Moderna") and Immatics N.V. (NASDAQ:IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.

Moderna & Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

The consensus price target hints at a 45.8% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Immatics (IMTX)? Wall Street Analysts Think 45.78%

Tuebingen, Germany and Houston , TX, August 17 , 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended June 30, 2023.

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Tuebingen, Germany and Houston, Texas , August 10 , 202 3 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the initiation of a Phase 1/2 clinical trial with its proprietary Bispecific T cell engaging receptor (TCER®) IMA402. IMA402 is the second product candidate in Immatics' TCER® pipeline of next-generation, half-life extended bispecific molecules to enter clinical development. It targets an HLA-A*02:01-presented peptide derived from PRAME, a clinically established cancer target frequently expressed in a large variety of solid tumors.

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Bristol-Myers Squibb Company made a $35 million equity investment into Immatics N.V. The partnership with Bristol-Myers Squibb brought $15 million opt-in payment; Immatics also is eligible to earn up to $490 million in milestone payments in addition to tiered royalties on net product sales. ACTengine IMA203 was able to achieve a confirmed objective response rate of 67% in 11 heavily pre-treated solid tumor PRAME patients in Cohort A of the phase 1b study.

Immatics: Additional Gains Possible Q4 Of 2023 With Data Update Of IMA203

Immatics recently posted updated data and went up a lot. IMTX stock is up hugely in the last 4 months. The company is developing solid tumor biologics and has a decent cash runway.

Immatics Is Increasingly Becoming Interesting

Bristol-Myers

Shares of Immatics N.V. IMTX, +0.08% gained more than 8% premarket on Monday after the clinical-stage biopharma company said it had received a $35 million equity investment from Bristol Myers Squibb Co. BMY, +1.43%.

Immatics shares jump after investment from Bristol Myers Squibb

Tuebingen , Germany and Houston , TX , Ju ly 24 , 202 3 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that Bristol Myers Squibb (NYSE: BMY) has made a $35 million equity investment in Immatics. Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of $14.461. Additionally, Bristol Myers Squibb has the right to appoint a member to the Immatics Scientific Advisory Board.

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Immatics (IMTX) Surges 7.5%: Is This an Indication of Further Gains?

Tuebingen , Germany and Houston, TX , May 16 , 20 2 3 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2023.

Immatics Announces First Quarter 2023 Financial Results and Business Update

Immatics (IMTX) Moves 27.5% Higher: Will This Strength Last?

Immatics announced encouraging interim data from a phase 1b clinical study. The company plans to provide another update in the fourth quarter of 2023.

Why Immatics Stock Is Soaring Today

Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

Tuebingen, Germany & Houston, May 1, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option and entered into an exclusive worldwide license for the first T cell receptor engineered T cell therapy (TCR-T) candidate from their ongoing collaboration.

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

Tuebingen , Germany and Houston, TX , March 2 1 , 20 2 3 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2022.

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Immatics (IMTX) delivered earnings and revenue surprises of -3.23% and 13.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates

Tuebingen , Germany and Houston, Texas , November 1 7 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended September 30, 2022.

Immatics Announces Third Quarter 2022 Financial Results and Business Update

The average of price targets set by Wall Street analysts indicates a potential upside of 76.9% in Immatics (IMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Immatics NV Stock (IMTX)